| Accession |
PRJCA016211 |
| Title |
Phase II clinical trial of PD-1 antibody SHR-1210 combined with apatinib mesylate versus adriamycin combined with ifosfamide in the treatment of soft tissue sarcoma |
| Relevance |
Medical |
| Data types |
clinical,image,Metabolic,Biomarker data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate whether SHR-1210 plus apatinib is superior to doxorubicin plus ifosfamide in Progression Free Survival (PFS) in patients with soft tissue sarcoma |
| Sample scope |
Multiisolate |
| Release date |
2023-04-12 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
wanqiu
liang (wanqiu.liang@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2023-04-12 |
